Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL813305 | 0.97 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAMAPK1RAPGEF4CYP1A2 | |
| Hydrochloric Acid SCHEMBL814062 | 0.89 | MAPK1 (0.43) | SMN1; SMN2MAPK1CYP1A2CYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL812454 | 0.89 | RAPGEF4 (0.35) | RAPGEF4CARM1 | |
| Hydrochloric Acid SCHEMBL814290 | 0.88 | MAPK1 (0.35) | SMN1; SMN2MAPK1RAPGEF4CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL813075 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPK1CYP1A2CYP3A4NLRP3 | |
| Bromide SCHEMBL813884 | 0.86 | RAPGEF4 (0.35) | RAPGEF4CARM1 | |
| Bromide SCHEMBL813566 | 0.86 | MAPK1 (0.43) | SMN1; SMN2MAPK1CYP1A2CYP3A4MAPT | |
| Bromide SCHEMBL820820 | 0.85 | MAPK1 (0.35) | SMN1; SMN2MAPK1RAPGEF4CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL813590 | 0.85 | RAPGEF4 (0.32) | RAPGEF4CARM1 | |
| Hydrochloric Acid SCHEMBL813315 | 0.85 | KMT2A (0.37) | SMN1; SMN2GAAMAPK1RAPGEF4NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | disclosed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | disclosed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1641842-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | Exxonmobil Chemical Patents Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004106390-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | SMN1; SMN2 1110/4885GAA 3583/4885MAPK1 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.